Tardive dyskinesia from atypical antipsychotic agents in patients with mood disorders in a clinical setting
Background There is a paucity of information on the risks and clinical characteristics of
tardive dyskinesia with atypical antipsychotic agents in patients with mood and anxiety
disorders in clinical practice. Methods: The authors retrospectively screened the charts of
268 patients with a mood or anxiety disorder treated with atypical antipsychotic agents from
a psychiatric practice. Fifteen patients who developed tardive dyskinesia were identified and
further data was collected on these patients. Results Tardive dyskinesia occurred in 5.9% of …
tardive dyskinesia with atypical antipsychotic agents in patients with mood and anxiety
disorders in clinical practice. Methods: The authors retrospectively screened the charts of
268 patients with a mood or anxiety disorder treated with atypical antipsychotic agents from
a psychiatric practice. Fifteen patients who developed tardive dyskinesia were identified and
further data was collected on these patients. Results Tardive dyskinesia occurred in 5.9% of …
Background
There is a paucity of information on the risks and clinical characteristics of tardive dyskinesia with atypical antipsychotic agents in patients with mood and anxiety disorders in clinical practice.
Methods: The authors retrospectively screened the charts of 268 patients with a mood or anxiety disorder treated with atypical antipsychotic agents from a psychiatric practice. Fifteen patients who developed tardive dyskinesia were identified and further data was collected on these patients.
Results
Tardive dyskinesia occurred in 5.9% of patients after exposure to an atypical antipsychotic agent for a mean of 28.7 months (range: 1–83). The average dosage of the offending agent in chlorpromazine equivalents was 350 mg/day (range: 67–969). All patients experienced oral-buccal-lingual stereotypy, which was frequently severe in nature, but completely resolved in all but one patient. Most patients (90.9%) who consented to a second trial of an atypical antipsychotic did not experience a relapse of TD.
Limitations: All patients were treated in a clinical practice setting by a single psychiatrist, which may limit the generalizability of the findings.
Conclusions
The observed rate of TD represents a real world estimate of the risk of TD with atypical antipsychotic agents in patients with mood disorders. Fortunately, with early recognition symptoms appear to be reversible and further treatment with another atypical antipsychotic does not necessarily lead to relapse.
Elsevier
以上显示的是最相近的搜索结果。 查看全部搜索结果